⚕ GalenOps CRO console
← SITE005 (FRA)

SITE005-0365

completed
Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer Phase III · Site: SITE005 (FRA) (Dr. Muller) · consented 2023-05-02
Adverse events
9
Serious AEs
1
Open data queries
0
Luna dropout signal
–

Adverse events

moderate assessed 2026-08-18

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-06-18 (study day 34); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Nausea — outcome: UNKNOWN; onset 2023-06-25 (study day 41); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Vomiting — outcome: RECOVERED/RESOLVED; onset 2023-09-01 (study day 109); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-10-04 (study day 142); relationship: N

mild assessed 2026-08-18

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-10-31 (study day 169); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-11-17 (study day 186); relationship: N

moderate assessed 2026-08-18

Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2024-02-21 (study day 282); relationship: not assessed

severe serious assessed 2026-08-18

Grade 3 Fatigue — outcome: RECOVERED/RESOLVED; onset 2024-02-25 (study day 286); relationship: N; serious criteria: hospitalization

mild assessed 2026-08-18

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2024-03-30 (study day 320); relationship: N

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.